Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys

Brain Res. 1998 Sep 28;806(2):292-6. doi: 10.1016/s0006-8993(98)00777-x.

Abstract

Opiate receptor avidity, roughly equivalent to the ratio of unoccupied receptor density to the receptor dissociation constant (B'max/KD), was measured in four MPTP (1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine)-lesioned rhesus monkeys and nine normal controls with positron emission tomography (PET) and 6-deoxy-6-beta-[18F]fluoronaltrexone (cyclofoxy, CF), a mu- and kappa-opiate receptor antagonist. Although the MPTP-lesioned monkeys were dopamine deficient as measured with [18F]-L-fluorodopa ([18F]-DOPA) and PET [Doudet et al., 6-[18F]-L-DOPA imaging of the dopamine neostriatal system in normal and clinically normal-MPTP-treated rhesus monkeys, Exp. Brain Res. 78 (1989) 69-80], they had clinically recovered from the acute motor effects of MPTP exposure. Opiate receptor avidity was found to be reduced by 30-35% in the opiate-receptor rich areas of caudate, anterior putamen, thalamus, and amygdala of the MPTP-lesioned animals. The results suggest that opiate pathways make a significant contribution to the adjustment of cortico-striatal-thalamic pathway activity and thereby to behavior in rhesus monkeys following dopamine loss.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology*
  • Animals
  • Brain / diagnostic imaging
  • Brain / drug effects*
  • Brain / metabolism*
  • Dopamine Agents / pharmacology*
  • In Vitro Techniques
  • Macaca mulatta
  • Naltrexone / analogs & derivatives
  • Narcotic Antagonists
  • Receptors, Opioid / metabolism*
  • Reference Values
  • Tissue Distribution
  • Tomography, Emission-Computed

Substances

  • Dopamine Agents
  • Narcotic Antagonists
  • Receptors, Opioid
  • Naltrexone
  • 6-deoxy-6-fluoronaltrexone
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine